Gram-negative bacteremia upon hospital admission: When should Pseudomonas aeruginosa be suspected?

Clinical Infectious Diseases

Volumn 48, Issue 5, 2009, Pages 580-586

  Schechner, Vered ^a,e   Nobre, Vandack ^b   Kaye, Keith S ^c   Leshno, Moshe ^a   Giladi, Michael ^a   Rohner, Peter ^b   Harbarth, Stephan ^b   Anderson, Deverick J ^c   Karchmer, Adolf W ^d   Schwaber, Mitchell J ^a   Carmeli, Yehuda ^a,d  

^a TEL AVIV UNIVERSITY   (Israel)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BACTEREMIA; CONTROLLED STUDY; ENTEROBACTERIACEAE; FEMALE; GRAM NEGATIVE INFECTION; HOSPITAL ADMISSION; HUMAN; IMMUNOCOMPETENCE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; RISK ASSESSMENT; AGE; DIFFERENTIAL DIAGNOSIS; ENTEROBACTERIACEAE INFECTION; HOSPITALIZATION; IMMUNE DEFICIENCY; INDWELLING CATHETER; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; PSEUDOMONAS INFECTION; RISK FACTOR;

ANTIINFECTIVE AGENT;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; CATHETERS, INDWELLING; DIAGNOSIS, DIFFERENTIAL; ENTEROBACTERIACEAE INFECTIONS; FEMALE; HOSPITALIZATION; HUMANS; IMMUNOCOMPROMISED HOST; MALE; MIDDLE AGED; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 60549109763     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/596709     Document Type: Article

References (27)

1. Gaynes R, Edwards JR. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis 2005; 41:848-54.
2. Pier G, Ramphal R. Pseudomonas aeruginosa. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 6th ed. Philadelphia: Elsevier/Churchill Livingstone, 2005:2587-615.
3. Hatchette TF, Gupta R, Marrie TJ. Pseudomonas aeruginosa community-acquired pneumonia in previously healthy adults: case report and review of the literature. Clin Infect Dis 2000; 31:1349-56.
4. Leibovici L, Shraga I, Drucker M, Konigsberger H, Samra Z, Pitlik SD. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med 1998; 244:379-86.
5. Harbarth S, Garbino J, Pugin J, Romand JA, Lew D, Pittet D. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med 2003; 115:529-35.
6. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000; 118:146-55.
7. Lodise TP, McKinnon PS, Swiderski L, Rybak MJ. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis 2003; 36:1418-23.
8. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34:1589-96.
9. Kang CI, Kim SH, Park WB, et al. Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother 2005; 49:760-6.
10. Kang CI, Kim SH, Kim HB, et al. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis 2003; 37:745-51.
11. Micek ST, Lloyd AE, Ritchie DJ, Reichley RM, Fraser VJ, Kollef MH. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 2005; 49:1306-11.
12. Vidal F, Mensa J, Almela M, et al. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the in-fluence of antibiotic treatment: analysis of 189 episodes. Arch Intern Med 1996; 156:2121-6.
13. Chamot E, Boffi El Amari E, Rohner P, Van Delden C. Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 2003; 47:2756-64.
14. Manthous CA, Amoateng-Adjepong Y. Empiric antibiotic use and resistant microbes: a "catch-22" for the 21st century. Chest 2000; 118:9-11.
15. Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 1999; 43:1379-82.
16. Kang CI, Kim SH, Park WB, et al. Risk factors for antimicrobial resistance and influence of resistance on mortality in patients with bloodstream infection caused by Pseudomonas aeruginosa. Microb Drug Resist 2005; 11:68-74.
17. Clinical and Laboratory Standards Institute. Performance standards for antimibrobial susceptibility testing; 16th informational supplement. Approved standard M100-S16. Wayne, PA: CLSI, 2006.
18. Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of illness in the aged. The Index of Adl: a standardized measure of biological and psychosocial function. JAMA 1963; 185:914-9.
19. Hastie T, Tibshirani R, Friedman JH. The elements of statistical learning: data mining, inference, and prediction New York: Springer, 2001.
20. Berthold M, Hand DJ. Intelligent data analysis: an introduction. Berlin, New York: Springer, 1999.
21. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27:157-72; discussion 207-12.
22. Kang CI, Kim SH, Park WB, et al. Clinical features and outcome of patients with community-acquired Pseudomonas aeruginosa bacteraemia. Clin Microbiol Infect 2005; 11:415-8.
23. Gransden WR, Leibovici L, Eykyn SJ, et al. Risk factors and a clinical index for diagnosis of Pseudomonas aeruginosa bacteremia. Clin Microbiol Infect 1995; 1:119-23.
24. Hughes WT, Armstrong D, Bodey GP, et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34:730-51.
25. Bodey GP, Jadeja L, Elting L. Pseudomonas bacteremia: retrospective analysis of 410 episodes. Arch Intern Med 1985; 145:1621-9.
26. Osih RB, McGregor JC, Rich SE, et al. Impact of empiric antibiotic therapy on outcomes in patients with Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 2007; 51:839-44.
27. Carmeli Y, Troillet N, Karchmer AW, Samore MH. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med 1999; 159:1127-32.